相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV
James Jansson et al.
AIDS (2013)
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
Hans-Juergen Stellbrink et al.
AIDS (2013)
Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials
C. Stephan et al.
HIV MEDICINE (2013)
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1-Infected Patients: Final 5-Year Results From STARTMRK
Juergen K. Rockstroh et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis
Peter Messiaen et al.
PLOS ONE (2013)
Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)
Eduardo Gotuzzo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
Calvin J. Cohen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials
Jose A. Perez-Molina et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings
Thomas B. Campbell et al.
PLOS MEDICINE (2012)
Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients
Kathleen E. Squires et al.
HIV CLINICAL TRIALS (2010)
Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study
Frank A. Post et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
R Qaqish et al.
Journal of the International AIDS Society (2010)
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals
Lawrence C. E. Mbuagbaw et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Efficacy and tolerability of initial antiretroviral therapy: a systematic review
Andrew Carr et al.
AIDS (2009)
Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir
Loveleen Bansi et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
Paul E. Sax et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
John A. Bartlett et al.
AIDS (2006)
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
K Squires et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily
GJ Yuen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection
LH Wang et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
Atazanavir: New option for treatment of HIV infection
DV Havlir et al.
CLINICAL INFECTIOUS DISEASES (2004)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
M Egger et al.
LANCET (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Risk factor analysis of hypersensitivity reactions to abacavir
W Symonds et al.
CLINICAL THERAPEUTICS (2002)
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
S Hetherington et al.
LANCET (2002)
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
S Mallal et al.
LANCET (2002)
分享论文
